The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Did FDA safety warnings and CMS coverage restrictions improve guideline adherence for ESA use for patients with myelodysplastic syndromes?
Franklin Hendrick
No relevant relationships to disclose
Maria R. Baer
No relevant relationships to disclose
Steven Gore
Consultant or Advisory Role - GlaxoSmithKline; Novartis
Research Funding - GlaxoSmithKline; Novartis
Sheila Weiss Smith
No relevant relationships to disclose
Amy J. Davidoff
Consultant or Advisory Role - GlaxoSmithKline (I); Novartis (I)
Research Funding - GlaxoSmithKline; Novartis